New PET tracer for prostate cancer enters human testing
NCT ID NCT07149831
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage trial is testing a new imaging agent called Flotufolastat F-18 in 6 healthy Chinese adults. The tracer is designed to light up prostate cancer cells during PET scans. Researchers are checking how safe it is, where it goes in the body, and how much radiation it gives off. This is a first step before testing it in people with prostate cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Flotufolastat F-18 Injection
What this could lead to
If successful, this could lead to a more accurate PET imaging method for detecting prostate cancer, potentially improving diagnosis and treatment planning.
What could go wrong
This is a very early Phase I trial with only 6 healthy volunteers, not patients. It only tests safety and imaging properties, not whether it actually helps diagnose cancer better than existing methods.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chinese PLA General Hospital
RECRUITINGBeijing, Beijing Municipality, 100089, China
Contact Phone: •••-•••-•••• Email: •••••@•••••